How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,345 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

at high risk for this infection. Condition or disease Intervention/treatment Phase Clostridium Difficile Diarrhea Drug: Metronidazole Drug: Placebo Phase 4 Detailed Description: Clostridium Difficile infection or C. Diff (CDI) is an infection that causes severe diarrhea. Risk factors for this infection include hospitalization, the use of antibiotics, along with medications that decrease the acid in the stomach. This infection leads to a disease which is difficult to treat and can cause serious (...) Drug: Placebo Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days Other Name: corn starch pill Outcome Measures Go to Primary Outcome Measures : The Incidence of Clostridium Difficile Diarrhea in Both Study Groups at 30 Days Post Broad Spectrum Antibiotic Use. [ Time Frame: 30 days ] Secondary Outcome Measures : Determine Differences in Clostridium Difficile Diarrhea Incidence Between Patients on Piperacillin/Tazobactam vs. Patients on Ciprofloxacin. [ Time Frame: 30 days

2014 Clinical Trials

102. 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-4) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02120027 Recruitment Status : Terminated (Because of negative results

2014 Clinical Trials

103. Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

: February 2019 Keywords provided by Jeffrey Hyams, MD, Connecticut Children's Medical Center: IBS IBS-D SBI Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Diarrhea Irritable Bowel Syndrome Disease Pathologic Processes Signs and Symptoms, Digestive Signs and Symptoms Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Immunoglobulins Antibodies Immunologic Factors Physiological Effects of Drugs (...) Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2014 Clinical Trials

104. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02107196 Recruitment Status : Completed First Posted : April 8, 2014

2014 Clinical Trials

105. Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea (CJCV1-01) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02067676 Recruitment Status : Completed First Posted : February 20, 2014 Results First Posted : January 25, 2018 Last Update Posted : February 23

2014 Clinical Trials

106. Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan

Comparator: Placebo Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h. Other: Placebo Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate Outcome Measures Go to Primary Outcome Measures : use of antimicrobial medications [ Time Frame: within 5 days of enrollment ] Secondary Outcome Measures : Patient's perceived need for antibiotics [ Time Frame: Within 48 h of enrollment ] additional care obtained for diarrhea [ Time Frame (...) : within 48 h of enrollment ] Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness Additional care obtained for diarrheal illness [ Time Frame: within 5 days of enrollment ] Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness Disease severity

2014 Clinical Trials

107. Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.

. Outcome Measures Go to Primary Outcome Measures : Efficacy measured by the decrease in the intensity of diarrhea and / or anti-diarrheal consumption [ Time Frame: 1 month ] Effectiveness of acetylsalicylic acid versus diosmectite Secondary Outcome Measures : Toxicity [ Time Frame: Three months ] Diarrhea decrease 3 months after the introduction of acetylsalicylic acid or diosmectite; Proportion of patients with a decrease in the grade of diarrhea during the months following the introduction (...) Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2014 Clinical Trials

108. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-05) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02320318 Recruitment Status : Withdrawn First Posted : December 19, 2014

2014 Clinical Trials

109. Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea

Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02318992 Recruitment Status : Unknown Verified November 2016

2014 Clinical Trials

110. Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

, 2018 Sponsor: Montefiore Medical Center Information provided by (Responsible Party): Olga Aroniadis, Montefiore Medical Center Study Details Study Description Go to Brief Summary: The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome (IBS-D); (2) determine the impact of FMT on the intestinal microbiome of patients with IBS-D (...) Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2014 Clinical Trials

111. A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

from birth to < 2 years) or number of UBMs (for ages ≥ 2 years to < 18 years). Secondary Outcome Measures : Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days [ Time Frame: Up to day 19 ] SCR at EOT + 9 days was defined as CCR (EOT + 2 days) without CDAD recurrence until assessment at EOT +9 days during the follow-up period. Recurrence for ages from birth to < 2 years was defined as re-establishment of watery diarrhea after CCR to an extent that was greater than (...) A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers

2014 Clinical Trials

112. Lactose-free Milk in Infants With Acute Diarrhea in a Developing Country

Last Update Posted : February 15, 2019 Sponsor: American University of Beirut Medical Center Information provided by (Responsible Party): Mona Nabulsi, American University of Beirut Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether lactose-free milk will shorten the diarrhea duration and decrease its severity in formula-fed infants presenting to the Emergency Department (ED) or pediatric clinics with acute diarrhea. Condition (...) milk No Intervention: Regular infant milk Regular infant milk formula and anti-diarrheic diet for 7 days. Outcome Measures Go to Primary Outcome Measures : Diarrhea Duration [ Time Frame: From onset of illness till the day of last diarrheic stool passed. ] number of days with 3 or more loose or watery stools Secondary Outcome Measures : Weight Loss [ Time Frame: 7 days ] Percent weight loss from baseline Illness Visits [ Time Frame: 7 days ] Number of participants with illness visits

2014 Clinical Trials

113. 64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings

mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days) Other Name: Bovine colostrum Sham Comparator: No 64N Nutraceutical Culturally appropriate 12 ounce warm drink daily for 1 week (7 days). Other: No 64N Nutraceutical 12 ounce warm drink daily for 1 week (7 days) Outcome Measures Go to Primary Outcome Measures : Mortality from childhood diarrhea and pneumonia [ Time Frame: Assessed every 3 months for 4.5 years ] Secondary Outcome Measures : Medical visits for childhood (...) 64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings 64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2014 Clinical Trials

114. Olmesartan, Other Antihypertensives, and Chronic Diarrhea Among Patients Undergoing Endoscopic Procedures: A Case-Control Study. (PubMed)

those whose examination indication was diarrhea, and controls were those whose examination indication was esophageal reflux (EGD) or colorectal cancer screening (colonoscopy). We compared cases with controls with regard to the proportion of those listing olmesartan among their medications. Secondary exposures were the proportion of those taking nonolmesartan ARBs or other antihypertensive medications. We also examined biopsy results to determine whether there were histologic changes associated (...) of celiac disease (P=.61) or microscopic colitis (P=1.0), respectively.Our findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely.Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Full Text available with Trip Pro

2014 Mayo Clinic Proceedings

115. Brilinta (ticagrelor) Tablets - medical review

Brilinta (ticagrelor) Tablets - medical review CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022433Orig1s000 MEDICAL REVIEW(S) DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS Complete Response Review Addendum Sponsor Safety Reporting Submissions: NDA 22-433 and IND 65,808 SD 632 Drug: ticagrelor (Brilinta™) Indication: reduce the rate of thrombotic events in patients with acute coronary syndromes (ACS) Sponsor: AstraZeneca Review date: June 8, 2011 Reviewer: Thomas A. Marciniak, M.D (...) . Medical Team Leader On April 20, 2011, we met with AstraZeneca (AZ) staff to discuss progress on the reviews of the complete response for NDA 22-433. Because my review and that of the IND reviewer, Dr. Martin Rose, had suggested significant problems with AZ’s handling of serious adverse events (SAEs), I added to the end of the agenda a discussion of these problems. The minutes for the meeting filed on May 19, 2011, summarize that discussion as follows: “There was some discussion regarding

2011 FDA - Drug Approval Package

116. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions CADTH Technology Report Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary (...) Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses Issue 133 November 2010Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Cite as: Banerjee S, Brown A, McGahan L, Asakawa K, Hutton B, Clark M, Severn M, Sharma M, Cox JL. Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome

2011 EvidenceUpdates

117. Fidaxomicin vs. Vancomycin for C. difficile Diarrhea: Fidaxomicin for C. difficile diarrhea

Fidaxomicin vs. Vancomycin for C. difficile Diarrhea: Fidaxomicin for C. difficile diarrhea Fidaxomicin in C. difficile Diarrhea - Wiki Journal Club Fidaxomicin in C. difficile Diarrhea From Wiki Journal Club (Redirected from ) Jump to: , Louie TJ, et al. "Fidaxomicin versus Vancomycin for Clostridium difficile Infection". The New England Journal of Medicine . 2011. 365(5):422-431. • • Contents Clinical Question In patients with Clostridium difficile -associated diarrhea, is treatment (...) with fidaxomicin non-inferior to vancomycin in terms of clinical cure? Bottom Line Fidaxomicin was noninferior to vancomycin in achieving rates of clinical cure among patients with Clostridium difficile -associated diarrhea and resulted in fewer recurrent infections. Major Points Clostridium difficile -associated diarrhea (CDAD) is a major adverse effect of antibiotic usage and its incidence is on the rise, particularly among hospitalized patients receiving broad-spectrum antibiotics. While the trial (2007

2011 Wiki Journal Club

118. Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

difficile. Has a colostomy. Intraabdominal surgery within the last 60 days. Evidence of active, severe colitis. History of short gut syndrome or motility disorders. Requires the regular use of medications that affect bowel motility (e.g., metoclopramide, narcotics, loperamide). Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy). Planned surgery requiring perioperative antibiotics within 6 months of study enrollment. Life expectancy of < 12 months. Compromised immune system (...) Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2013 Clinical Trials

119. A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01870895 Recruitment Status

2013 Clinical Trials

120. A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01896583 Recruitment Status : Completed First Posted : July 11, 2013 Last

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>